B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

  • ID: 3746950
  • Drug Pipelines
  • 1066 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Biogenomics Limited
  • EpiZyme, Inc.
  • Incyte Corporation
  • Mirati Therapeutics Inc.
  • Philogen S.p.A.
  • MORE
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

Summary

‘B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016’, provides an overview of the B-Cell Non-Hodgkin Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Non-Hodgkin Lymphoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma
- The report reviews pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved B-Cell Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses B-Cell Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Biogenomics Limited
  • EpiZyme, Inc.
  • Incyte Corporation
  • Mirati Therapeutics Inc.
  • Philogen S.p.A.
  • MORE
Introduction

B-Cell Non-Hodgkin Lymphoma Overview

Therapeutics Development

B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies

B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes

B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance

B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies

B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes

B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development

B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment

Drug Profiles

B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates

B-Cell Non-Hodgkin Lymphoma - Dormant Projects

B-Cell Non-Hodgkin Lymphoma - Discontinued Products

B-Cell Non-Hodgkin Lymphoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2016

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Development by Companies, H1 2016 (Contd..6)

Number of Products under Development by Companies, H1 2016 (Contd..7)

Number of Products under Development by Companies, H1 2016 (Contd..8)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Products under Development by Companies, H1 2016 (Contd..8)

Products under Development by Companies, H1 2016 (Contd..9)

Products under Development by Companies, H1 2016 (Contd..10)

Products under Development by Companies, H1 2016 (Contd..11)

Products under Development by Companies, H1 2016 (Contd..12)

Products under Development by Companies, H1 2016 (Contd..13)

Products under Development by Companies, H1 2016 (Contd..14)

Products under Development by Companies, H1 2016 (Contd..15)

Products under Development by Companies, H1 2016 (Contd..16)

Products under Development by Companies, H1 2016 (Contd..17)

Products under Development by Companies, H1 2016 (Contd..18)

Products under Development by Companies, H1 2016 (Contd..19)

Products under Development by Companies, H1 2016 (Contd..20)

Products under Development by Companies, H1 2016 (Contd..21)

Products under Development by Companies, H1 2016 (Contd..22)

Products under Development by Companies, H1 2016 (Contd..23)

Products under Development by Companies, H1 2016 (Contd..24)

Products under Development by Companies, H1 2016 (Contd..25)

Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)

B-Cell Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Arvinas, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by BeiGene, Ltd., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by BIND Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Biocon Limited, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Biogenomics Limited, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Bluebird bio, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Cell>Point, L.L.C., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co., Ltd., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Genosco, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunovaccine, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Limited, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by JHL Biotech, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Karus Therapeutics Limited, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB S.A., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by mAbxience S.A., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Medivation, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by MEI Pharma, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by OXIS International, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Selvita S.A., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by United BioPharma, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H1 2016

B-Cell Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

B-Cell Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects, H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H1 2016

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H1 2016

B-Cell Non-Hodgkin Lymphoma - Discontinued Products, H1 2016

B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H1 2016

B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H1 2016

B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H1 2016

B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H1 2016

List of Figures

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2016

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AB Science SA
AbbVie Inc.
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Affimed Therapeutics AG
Altor BioScience Corporation
Amgen Inc.
arGEN-X BV
Ariad Pharmaceuticals, Inc.
Arrien Pharmaceuticals, LLC
Arvinas, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Aurigene Discovery Technologies Limited
Bayer AG
BeiGene, Ltd.
BIND Therapeutics, Inc.
Bio-Path Holdings, Inc.
Biocon Limited
Biogenomics Limited
Biothera, Inc.
Bluebird bio, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Cell>Point, L.L.C.
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
Constellation Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc.
CTI BioPharma Corp.
Curis, Inc.
Cyclacel Pharmaceuticals, Inc.
Dynavax Technologies Corporation
eFFECTOR Therapeutics, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EpiZyme, Inc.
Erytech Pharma SA
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Genor BioPharma Co., Ltd.
Genosco
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
IGF Oncology, LLC.
Immune Design Corp.
ImmunoGen, Inc.
Immunomedics, Inc.
Immunovaccine, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Inflection Biosciences Limited
JHL Biotech, Inc.
Johnson & Johnson
Juno Therapeutics Inc.
Karus Therapeutics Limited
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Les Laboratoires Servier SAS
LFB S.A.
Mabion SA
mAbxience S.A.
MedImmune, LLC
Medivation, Inc.
MEI Pharma, Inc.
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Mirna Therapeutics, Inc.
Molecular Templates Inc.
Molplex Ltd.
MorphoSys AG
Neumedicines Inc.
Nimbus Therapeutics, LLC
Nordic Nanovector ASA
Novartis AG
NovImmune SA
Onconova Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
OXIS International, Inc.
Pfizer Inc.
Pharmacyclics, Inc.
Philogen S.p.A.
Portola Pharmaceuticals, Inc.
ProNAi Therapeutics, Inc.
RedHill Biopharma Ltd.
Regeneron Pharmaceuticals, Inc.
Respiratorius AB
Rhizen Pharmaceuticals S.A.
Sandoz International GmbH
Sanofi
Seattle Genetics, Inc.
Selvita S.A.
Shanghai Henlius Biotech Co., Ltd.
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Taiho Pharmaceutical Co., Ltd.
Takara Bio Inc.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
The International Biotechnology Center (IBC) Generium
Theravectys SA
United BioPharma, Inc.
Unum Therapeutics, Inc.
Vivolux AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll